openPR Logo
Press release

Adalimumab Market Growth, Size, Share and Forecast 2020-2026

05-22-2020 11:57 AM CET | Health & Medicine

Press release from: Orion Market Research

Adalimumab Market Growth, Size, Share and Forecast 2020-2026

The adalimumab market is expected to witness a negative CAGR during the forecast period 2020-2026. Adalimumab is a biological drug sold by AbbVie Inc., under the brand name Humira for the treatment of various diseases including arthritis, Crohn's disease, ulcerative colitis, and others. The company was witnessing a significant growth until the patent of the drugs doesn't expire in the US and Europe. In 2019, Humira generated revenue of $19.1 billion as compared to $19.9 billion in 2018.

A full report of Global Adalimumab Market is available at https://www.omrglobal.com/industry-reports/adalimumab-market

The US is the major market of the adalimumab market. As in 2019, around 77% of the total Humira revenue was generated from the US which was around $14.8 billion. It is expected that even when the biosimilar will be introduced to the US market, the market penetration of Humira will be considerably high. AbbVie Inc. has lost its patent in December 2016 in the US, however, due to multiple agreements with other biosimilar manufacturing companies, AbbVie is expected to maintain a monopoly in the country. Amgen Inc. was the first company to get approval for a biosimilar for adalimumab in September 2016 however in September 2017, the company got into an agreement with AbbVie Inc., to delay the launch of the drug till 31st January 2023. In May 2019, AbbVie Inc. collaborated with Boehringer Ingelheim International GmbH, not to manufacturer adalimumab biosimilar till 1st July 2023. Similarly in October 2018, Novartis AG got the FDA approval for Hyrimoz (adalimumab-adaz) however it will start the marketing only after 30th September 2023.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/adalimumab-market

Europe is expected to show a modest growth rate during the forecast period. The European adalimumab market is in the transition phase from branded biological drugs to the biosimilar. Both Humira and its biosimilars are available in the European market. After the patent expiration of Humira in Europe, four biosimilars are available in the market that are Amgen's Amgevita, Biogen's Imraldi, Sandoz's Hyrimoz, and Terumo Corp.'s Hulio. All these companies are offering a huge discount to remain competitive in the market. For instance, in order to maintain a monopoly in the adalimumab market, AbbVie Inc., is offering high discounts to the hospitals. The company has offered a discount of up to 89% to the Dutch health care system as Amegen was offering a discount of around 85% to the Santeon group (an alliance of seven large hospitals in the Netherlands). Moreover, AbbVie Inc. offers a discount to a hospital only when the hospital buys branded products for all the patients. Some instances were witnessed when some hospitals in the Netherlands wants to purchase Humira only for the patients who can't be shifted to the biosimilar medicine.

Asia-Pacific is expected to showcase significant growth during the forecast period. The increase in patient pool and rising healthcare expenditure is expected to provide significant market growth during the forecast period. Humira is not approved in the Indian market however a number of biosimilars of it are available in the country. Cadila Healthcare Ltd. had launched the adalimumab biosimilar in December 2014 under brand name Exemptia. Torrent Pharmaceutical Ltd. launched the adalimumab biosimilar under the brand name Adfrar in 2016. Other companies offering adalimumab in India include Reliance Life Sciences Pvt. Ltd., Hetero Healthcare Ltd., and so on. Bio-Thera Solutions Ltd. and Innovent Biologics, Inc. are some of the major companies working in the adalimumab market in China whereas Fujifilm Kyowa Kirin Biologics Co. Ltd. is a major Japanese company working in the market.

Global Preventive Vaccine Market- Segmentation

By Disease

o Rheumatoid arthritis
o Psoriatic arthritis
o Crohn's disease
o Ulcerative colitis
o Others

By Type

o Branded
o Generic

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/adalimumab-market

Global Preventive Vaccine Market- Segment by Region

North America

o United States
o Canada

Europe

o Germany
o United Kingdom
o France
o Spain
o Italy
o Rest of Europe

Asia-Pacific

o China
o Japan
o India
o Rest of Asia-Pacific

Rest of the World

o Middle East & Africa
o Latin America

Company Profiles

o AbbVie Inc.
o Alvotech hf
o Amgen Inc.
o Bio-Thera Solutions Ltd.
o Boehringer Ingelheim International GmbH
o Bristol-Myers Squibb Co.
o Cadila Healthcare Ltd.
o Emcure Pharmaceuticals Ltd.
o Fujifilm Kyowa Kirin Biologics Co. Ltd.
o Hetero Healthcare Ltd.
o Innovent Biologics, Inc.
o Merchant Logo
o Novartis International AG (Sandoz)
o Pfizer Inc.
o Reliance Life Sciences Pvt. Ltd.
o Samsung Bioepis Co. Ltd
o Terumo Corp.
o Torrent Pharmaceuticals Ltd.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Adalimumab Market Growth, Size, Share and Forecast 2020-2026 here

News-ID: 2054971 • Views:

More Releases from Orion Market Research

Road Marking Paint Market : A Guide to Understanding the Process
Road Marking Paint Market : A Guide to Understanding the Process
The Road Marking Paint Market, valued at approximately USD 5.02 billion in 2023, is projected to reach around USD 7.69 billion by 2033, growing at a compound annual growth rate (CAGR) of 4.36% from 2024 to 2033. Road Marking Paint Market Overview The Road Marking Paint Market is steadily expanding, driven by burgeoning infrastructure investments and the need for improved road safety. Governments and municipalities are increasingly allocating funds toward both new
Outboard Boat Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Outboard Boat Market Size Analysis, Competitive Insights, Leading Players and Gr …
The Outboard Boats Market, valued at approximately USD 5.74 billion in 2023, is projected to grow to around USD 14 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 9% over the 2024-2033 period. Outboard Boat Market Overview The Outboard Boat Market continues to expand robustly, fueled largely by rising demand for recreational boating, favorable economic conditions, and the appeal of leisure marine activities. Innovations in outboard motor technology-including
Mobile Ticketing Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Mobile Ticketing Market Size Analysis, Competitive Insights, Leading Players and …
The Mobile Ticketing Market, valued at about USD 2.9 billion in 2023, is anticipated to grow to approximately USD 11.39 billion by 2033, reflecting a robust CAGR of 16.7% from 2024 to 2033. Mobile Ticketing Market Overview The Mobile Ticketing Market is undergoing rapid expansion, driven primarily by the global surge in smartphone usage and consumer preference for contactless, digital experiences. This growth is further propelled by widespread adoption of digital payments,
Metal Alloy Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Metal Alloy Market Size Analysis, Competitive Insights, Leading Players and Grow …
The Metal Alloy Market, valued at approximately USD 301.7 billion in 2023, is projected to reach USD 533.9 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2033. Metal Alloy Market Overview The Metal Alloy Market is experiencing steady, long-term expansion, driven by growing demand from key sectors such as automotive, aerospace, construction, and electronics. Applications in next-generation vehicles and aircraft are pushing interest in

All 5 Releases


More Releases for AbbVie

Endometriosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsi …
The Key Endometriosis Companies in the market include - AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others. DelveInsight's "Endometriosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth
The Future of Refractory Multiple Myeloma Therapy: 75+ Companies Advancing the C …
Pharmaceutical pioneers are unlocking new opportunities in Refractory Multiple Myeloma treatment for metabolic disorders. DelveInsight's 'Refractory Multiple Myeloma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Refractory Multiple Myeloma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Refractory Multiple Myeloma pipeline domain. For Refractory Multiple Myeloma emerging drugs, the Refractory Multiple Myeloma pipeline analysis report
Pouchitis Treatment Market | AbbVie, Alfasigma, Astellas Pharma, AstraZeneca
The global pouchitis treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the pouchitis treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth of the
Biopharmaceuticals Market Worth Observing Growth: Johnson & Johnson, Roche, AbbV …
Latest Market intelligence report released by HTF MI with title "Global Biopharmaceuticals Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)" is designed covering micro level of analysis by manufacturers and key business segments. The Global Biopharmaceuticals Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through
Leukemia Therapeutics Market Worth Observing Growth | Pfizer, Sanofi, AbbVie
Latest publication on 'Global Leukemia Therapeutics Market – By Disease Type (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia), By Drug Class (Small Molecules and Biologics), and By Regions (North America, Europe, Asia Pacific, and Rest of the World): Forecast up to 2025' is added in HTF MI research reporsitory provides in-depth analysis, Competitive scenario, and future market trends and strategies. The regional analysis
Immunotherapy Drugs Market Next Big Thing | Amgen, GlaxoSmithKline, AbbVie
AMA Research added a comprehensive research document of 200+ pages on 'Immunotherapy Drugs' market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are: F. Hoffmann-La Roche AG (Switzerland)